A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Metastases, Cancer
Both
Metastases, Cancer
Trial Information
A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Inclusion Criteria:
- Histologic or cytologic diagnosis of metastatic or locally advanced cancer
- Prior chemotherapy is allowed
- Adequate bone marrow, liver and kidney function
Exclusion Criteria:
- Prior treatment with ALIMTA
- Brain metastasis
- Pregnancy or breast feeding
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
1310
NCT ID:
NCT00034463
Start Date:
Completion Date:
Related Keywords:
- Metastases
- Cancer
- metastatic cancer
- chemotherapy
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
Name | Location |
|---|---|
| For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. | San Antonio, Texas |
